| http://www.w3.org/ns/prov#value | - sease, October 2010, which states that: 'In general, Phase 3 studies should use endpoints such as mortality and cardiovascular or heart failure hospitalizations, whereas endpoints, such as ejection fraction, that have not been validated as surrogates for clinical outcome are not considered to be acceptable as primary efficacy endpoints for pivotal trials'.The American Heart Association presentati
|
